Long-term Normothermic Machine Preservation of Partial Livers: First Experience With 21 Human Hemi-livers.


Journal

Annals of surgery
ISSN: 1528-1140
Titre abrégé: Ann Surg
Pays: United States
ID NLM: 0372354

Informations de publication

Date de publication:
01 11 2021
Historique:
pubmed: 3 8 2021
medline: 23 11 2021
entrez: 2 8 2021
Statut: ppublish

Résumé

The aim of this study was to maintain long-term full function and viability of partial livers perfused ex situ for sufficient duration to enable ex situ treatment, repair, and regeneration. Organ shortage remains the single most important factor limiting the success of transplantation. Autotransplantation in patients with nonresectable liver tumors is rarely feasible due to insufficient tumor-free remnant tissue. This limitation could be solved by the availability of long-term preservation of partial livers that enables functional regeneration and subsequent transplantation. Partial swine livers were perfused with autologous blood after being procured from healthy pigs following 70% in-vivo resection, leaving only the right lateral lobe. Partial human livers were recovered from patients undergoing anatomic right or left hepatectomies and perfused with a blood based perfusate together with various medical additives. Assessment of physiologic function during perfusion was based on markers of hepatocyte, cholangiocyte, vascular and immune compartments, as well as histology. Following the development phase with partial swine livers, 21 partial human livers (14 right and 7 left hemi-livers) were perfused, eventually reaching the targeted perfusion duration of 1 week with the final protocol. These partial livers disclosed a stable perfusion with normal hepatic function including bile production (5-10 mL/h), lactate clearance, and maintenance of energy exhibited by normal of adenosine triphosphate (ATP) and glycogen levels, and preserved liver architecture for up to 1 week. This pioneering research presents the inaugural evidence for long-term machine perfusion of partial livers and provides a pathway for innovative and relevant clinical applications to increase the availability of organs and provide novel approaches in hepatic oncology.

Sections du résumé

OBJECTIVE
The aim of this study was to maintain long-term full function and viability of partial livers perfused ex situ for sufficient duration to enable ex situ treatment, repair, and regeneration.
BACKGROUND
Organ shortage remains the single most important factor limiting the success of transplantation. Autotransplantation in patients with nonresectable liver tumors is rarely feasible due to insufficient tumor-free remnant tissue. This limitation could be solved by the availability of long-term preservation of partial livers that enables functional regeneration and subsequent transplantation.
METHODS
Partial swine livers were perfused with autologous blood after being procured from healthy pigs following 70% in-vivo resection, leaving only the right lateral lobe. Partial human livers were recovered from patients undergoing anatomic right or left hepatectomies and perfused with a blood based perfusate together with various medical additives. Assessment of physiologic function during perfusion was based on markers of hepatocyte, cholangiocyte, vascular and immune compartments, as well as histology.
RESULTS
Following the development phase with partial swine livers, 21 partial human livers (14 right and 7 left hemi-livers) were perfused, eventually reaching the targeted perfusion duration of 1 week with the final protocol. These partial livers disclosed a stable perfusion with normal hepatic function including bile production (5-10 mL/h), lactate clearance, and maintenance of energy exhibited by normal of adenosine triphosphate (ATP) and glycogen levels, and preserved liver architecture for up to 1 week.
CONCLUSION
This pioneering research presents the inaugural evidence for long-term machine perfusion of partial livers and provides a pathway for innovative and relevant clinical applications to increase the availability of organs and provide novel approaches in hepatic oncology.

Identifiants

pubmed: 34334640
doi: 10.1097/SLA.0000000000005102
pii: 00000658-202111000-00022
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

836-842

Informations de copyright

Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest: E.T.H. (Swiss Federal Institute of Technology in Zurich) (M. H., M. J. S., B. B., P. RvR., D.B.) and the University of Zurich (D.E., P.D., L.B.B. and P-A. C.) own/applied for patents on liver perfusion technology (PCT/EP2019/051252, PCT/EP20 17/068506). The authors report no other conflicts of interest.

Références

Dutkowski P, Linecker M, DeOliveira ML, et al. Challenges to liver transplantation and strategies to improve outcomes. Gastroenterology 2015; 148:307–323.
Giwa S, Lewis JK, Alvarez L, et al. The promise of organ and tissue preservation to transform medicine. Nat Biotechnol 2017; 35:530–542.
Eshmuminov D, Becker D, Bautista Borrego L, et al. An integrated perfusion machine preserves injured human livers for 1 week. Nat Biotechnol 2020; 38:189–198.
de Vries RJ, Tessier SN, Banik PD, et al. Supercooling extends preservation time of human livers. Nat Biotechnol 2019; 37:1131–1136.
Nasralla D, Coussios CC, Mergental H, et al. A randomized trial of normothermic preservation in liver transplantation. Nature 2018; 557:50–56.
Soubrane O, de Rougemont O, Kim KH, et al. Laparoscopic living donor left lateral sectionectomy: a new standard practice for donor hepatectomy. Ann Surg 2015; 262:757–761. discussion 761-3.
Huang V, Karimian N, Detelich D, et al. Split-liver ex situ machine perfusion: a novel technique for studying organ preservation and therapeutic interventions. J Clin Med 2020; 9:
Attard J, Osei-Brdom DC, Boteon Y, et al. Ex situ normothermic split liver machine perfusion: protocol for robust comparative controls in liver function assessment suitable for evaluation of novel therapeutic interventions in the pre-clinical setting. Front Surg 2021; 8:627332.
de Santibanes E, Clavien PA. Playing Play-Doh to prevent postoperative liver failure: the “ALPPS” approach. Ann Surg 2012; 255:415–417.
Raptis DA, Linecker M, Kambakamba P, et al. Defining benchmark outcomes for ALPPS. Ann Surg 2019; 270:835–841.
Mohkam K, Darnis B, Mabrut JY. Porcine models for the study of small-for-size syndrome and portal inflow modulation: literature review and proposal for a standardized nomenclature. J Hepatobiliary Pancreat Sci 2016; 23:668–680.
Nagino M, DeMatteo R, Lang H, et al. Proposal of a new comprehensive notation for hepatectomy: the “new world” terminology. Ann Surg 2021; DOI: 10.1097/SLA.0000000000004808.
doi: 10.1097/SLA.0000000000004808
Eshmuminov D, Schuler MJ, Becker D, et al. Bile formation in long-term ex situ perfused livers. Surgery 2021; 169:894–902.
Becker D, Hefti M, Schuler MJ, et al. Model assisted analysis of the hepatic arterial buffer response during ex vivo porcine liver perfusion. IEEE Trans Biomed Eng 2020; 67:667–678.
Becker D, Eshmuminov D, Keller R, et al. Automated insulin delivery—continuous blood glucose control during ex situ liver perfusion. IEEE Trans Biomed Eng 2020; PP.
Gottschalk M, Elmer A, Benden C, et al. Impact of cardiopulmonary resuscitation on organ donation in Switzerland. Swiss Med Wkly 2021; 151:w20413.
Kachaylo E, Tschuor C, Calo N, et al. PTEN down-regulation promotes beta-oxidation to fuel hypertrophic liver growth after hepatectomy in mice. Hepatology 2017; 66:908–921.
Tschuor C, Kachaylo E, Ungethum U, et al. Yes-associated protein promotes early hepatocyte cell cycle progression in regenerating liver after tissue loss. FASEB Bioadv 2019; 1:51–61.
Janda CY, Dang LT, You C, et al. Surrogate Wnt agonists that phenocopy canonical Wnt and beta-catenin signalling. Nature 2017; 545:234–237.
Line PD, Hagness M, Berstad AE, et al. A novel concept for partial liver transplantation in nonresectable colorectal liver metastases: the RAPID concept. Ann Surg 2015; 262:e5–e9.
Nadalin S, Settmacher U, Rauchfuss F, et al. RAPID procedure for colorectal cancer liver metastasis. Int J Surg 2020; 82S:93–96.
Rossler F, Sapisochin G, Song G, et al. Defining benchmarks for major liver surgery: a multicenter analysis of 5202 living liver donors. Ann Surg 2016; 264:492–500.
Petrowsky H, Fritsch R, Guckenberger M, et al. Modern therapeutic approaches for the treatment of malignant liver tumours. Nat Rev Gastroenterol Hepatol 2020; 17:755–772.
Sampaziotis F, Muraro D, Tysoe OC, et al. Cholangiocyte organoids can repair bile ducts after transplantation in the human liver. Science 2021; 371:839–846.
Kornmann B, Schaad O, Bujard H, et al. System-driven and oscillator-dependent circadian transcription in mice with a conditionally active liver clock. PLoS Biol 2007; 5:e34.
Sinturel F, Gerber A, Mauvoisin D, et al. Diurnal oscillations in liver mass and cell size accompany ribosome assembly cycles. Cell 2017; 169:651–663. e14.
Wei Y, Wang YG, Jia Y, et al. Liver homeostasis is maintained by midlobular zone 2 hepatocytes. Science 2021; 371:eabb1625.
Benhamouche S, Decaens T, Godard C, et al. Apc tumor suppressor gene is the “zonation-keeper” of mouse liver. Dev Cell 2006; 10:759–770.

Auteurs

Matteo Mueller (M)

Wyss Zurich, ETH Zurich/University of Zurich, Switzerland.
Department of Surgery and Transplantation, Swiss Hepato-Pancreato-Biliary (HPB) Center, University Hospital Zurich, Switzerland.

Max Hefti (M)

Wyss Zurich, ETH Zurich/University of Zurich, Switzerland.

Dilmurodjon Eshmuminov (D)

Wyss Zurich, ETH Zurich/University of Zurich, Switzerland.
Department of Surgery and Transplantation, Swiss Hepato-Pancreato-Biliary (HPB) Center, University Hospital Zurich, Switzerland.

Martin J Schuler (MJ)

Wyss Zurich, ETH Zurich/University of Zurich, Switzerland.

Richard X Sousa Da Silva (RX)

Wyss Zurich, ETH Zurich/University of Zurich, Switzerland.
Department of Surgery and Transplantation, Swiss Hepato-Pancreato-Biliary (HPB) Center, University Hospital Zurich, Switzerland.

Henrik Petrowsky (H)

Department of Surgery and Transplantation, Swiss Hepato-Pancreato-Biliary (HPB) Center, University Hospital Zurich, Switzerland.

Michelle L De Oliveira (ML)

Department of Surgery and Transplantation, Swiss Hepato-Pancreato-Biliary (HPB) Center, University Hospital Zurich, Switzerland.

Christian E Oberkofler (CE)

Department of Surgery and Transplantation, Swiss Hepato-Pancreato-Biliary (HPB) Center, University Hospital Zurich, Switzerland.

Catherine Hagedorn (C)

Wyss Zurich, ETH Zurich/University of Zurich, Switzerland.
Department of Surgery and Transplantation, Swiss Hepato-Pancreato-Biliary (HPB) Center, University Hospital Zurich, Switzerland.

Leandro Mancina (L)

Wyss Zurich, ETH Zurich/University of Zurich, Switzerland.
Department of Surgery and Transplantation, Swiss Hepato-Pancreato-Biliary (HPB) Center, University Hospital Zurich, Switzerland.

Achim Weber (A)

Department of Pathology and Molecular Pathology and Institute of Molecular Cancer Research (IMCR), University Zurich and University Hospital Zurich, Switzerland.

Brian Burg (B)

Wyss Zurich, ETH Zurich/University of Zurich, Switzerland.

Mark W Tibbitt (MW)

Wyss Zurich, ETH Zurich/University of Zurich, Switzerland.
Macromolecular Engineering Laboratory, Department of Mechanical and Process Engineering, ETH Zurich, Zurich, Switzerland.

Philipp Rudolf von Rohr (P)

Wyss Zurich, ETH Zurich/University of Zurich, Switzerland.
Transport Processes and Reactions Laboratory, Department of Mechanical and Process Engineering, ETH Zurich, Zurich, Switzerland.

Philipp Dutkowski (P)

Wyss Zurich, ETH Zurich/University of Zurich, Switzerland.
Department of Surgery and Transplantation, Swiss Hepato-Pancreato-Biliary (HPB) Center, University Hospital Zurich, Switzerland.

Dustin Becker (D)

Wyss Zurich, ETH Zurich/University of Zurich, Switzerland.

Lucia Bautista Borrego (L)

Wyss Zurich, ETH Zurich/University of Zurich, Switzerland.
Department of Surgery and Transplantation, Swiss Hepato-Pancreato-Biliary (HPB) Center, University Hospital Zurich, Switzerland.

Pierre-Alain Clavien (PA)

Wyss Zurich, ETH Zurich/University of Zurich, Switzerland.
Department of Surgery and Transplantation, Swiss Hepato-Pancreato-Biliary (HPB) Center, University Hospital Zurich, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH